Acquisitions (Details) - USD ($)		12 Months Ended
	Apr. 14, 2014	Dec. 31, 2015	Dec. 31, 2014
Allocation of purchase price
Goodwill			$ 16,902,466
Fair value of liability		$ 21,088,834	31,507,588
Shape Pharmaceuticals
Acquisitions
Percentage of share capital acquired	100.00%
Fair value of consideration transferred	$ 13,000,000
Allocation of purchase price
Cash and cash equivalents	71,792
Other current assets	320,464
Accounts payable	(138,645)
Deferred taxes	(16,879,659)
Contingent consideration and other liabilities	(28,932,339)
Legal expenses	121,873
Indefinite-lived intangible assets	41,575,516
Goodwill	16,902,466
Total purchase price	13,041,468
Goodwill recognized or deductible for tax purposes	0
Low end of range of undiscounted amounts	0
High end of range of undiscounted amounts	$ 64,500,000
Change in fair value recognized as operating expense		(10,400,000)	2,600,000
Fair value of liability		$ 21,100,000
Acquisition related costs expensed			400,000
Pro forma information
Net loss attributable to TetraLogic Pharmaceuticals Corporation			$ (36,469,877)
Basic loss per common share attributable to TetraLogic Pharmaceuticals Corporation (in dollars per share)			$ (1.64)
Diluted loss per common share attributable to TetraLogic Pharmaceuticals Corporation (in dollars per share)			$ (1.65)